OncoSec Medical Incorporated (ONCS) Bundle
A Brief History of OncoSec Medical Incorporated (ONCS)
Company Founding and Early Years
OncoSec Medical Incorporated (ONCS) was founded in 2011. The company is headquartered in San Diego, California. Initially, the firm focused on developing a novel approach to cancer treatment that utilizes electroporation technology to enhance the delivery of intratumoral therapies.
Technology and Product Development
The primary technology developed by OncoSec is known as ImmunoPulse, which combines electroporation with the administration of plasmid DNA to stimulate an immune response against tumors. The lead product candidate is ONCOS-102, designed for the treatment of melanoma and other solid tumors.
Clinical Trials and Progress
OncoSec initiated multiple clinical trials to evaluate the safety and efficacy of its therapies:
- The Phase II trial for metastatic melanoma commenced in 2012.
- In 2018, OncoSec reported positive results from a study combining ImmunoPulse with anti-PD-1 therapy, showing a higher overall response rate.
- As of October 2023, they have ongoing trials in various cancers, including breast and head & neck cancers.
Financial Performance
OncoSec has faced fluctuations in its financial stance since inception. Here are key financial figures:
| Year | Revenue (in million USD) | Net Income (in million USD) | R&D Expenses (in million USD) | Cash, Cash Equivalents (in million USD) |
|---|---|---|---|---|
| 2018 | 0.02 | (12.73) | 7.4 | 8.7 |
| 2019 | 0.03 | (13.58) | 8.1 | 5.5 |
| 2020 | 0.04 | (12.88) | 7.9 | 12.1 |
| 2021 | 0.05 | (15.22) | 9.5 | 10.3 |
| 2022 | 0.06 | (16.27) | 11.0 | 8.7 |
| 2023 | 0.08 | (17.51) | 12.4 | 15.2 |
Strategic Partnerships and Collaborations
OncoSec has been proactive in securing partnerships to enhance its research capabilities and expand its market reach:
- In 2019, OncoSec partnered with Merck to explore combinations of ImmunoPulse with pembrolizumab.
- Collaborations with academic institutions to leverage expertise in immuno-oncology.
Market Presence and Stock Performance
OncoSec Medical is publicly traded on the Nasdaq under the ticker symbol ONCS. The stock has experienced significant volatility:
- Stock price as of October 2023: $1.82
- Market capitalization: approximately $95 million
- 52-week range: $1.10 - $3.75
Future Directions
OncoSec aims to advance its clinical pipeline and expand its research into additional tumor types, focusing on enhancing its product offerings and improving patient outcomes.
A Who Owns OncoSec Medical Incorporated (ONCS)
Current Ownership Structure
As of the latest filings, the ownership of OncoSec Medical Incorporated is distributed among institutional investors, individual shareholders, and company insiders. The following table outlines the significant shareholders as of recent reports:
| Shareholder Type | Name | Ownership Percentage | Shares Held |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 8.1% | 1,500,000 |
| Institutional Investor | The Vanguard Group, Inc. | 7.5% | 1,400,000 |
| Insider | Daniel O'Connor (CEO) | 5.2% | 900,000 |
| Insider | Peter A. L. van de Wetering (CFO) | 4.8% | 800,000 |
| Individual Investor | Top 10 Individual Shareholders | 3.0% | 500,000 |
| Other Investors | Public Float | 71.4% | 12,500,000 |
Recent Stock Performance
OncoSec Medical Incorporated's stock has experienced significant volatility in recent months. The following data shows the stock performance metrics:
| Date | Opening Price | Closing Price | Volume |
|---|---|---|---|
| September 1, 2023 | $1.15 | $1.25 | 150,000 |
| October 1, 2023 | $1.20 | $1.10 | 200,000 |
| November 1, 2023 | $1.10 | $1.05 | 180,000 |
| December 1, 2023 | $1.25 | $1.30 | 220,000 |
Market Capitalization
As of October 2023, OncoSec Medical Incorporated's market capitalization stands at approximately $45 million.
Recent Institutional Investments
Several institutional investors have recently increased their stakes in OncoSec Medical Incorporated:
- BlackRock, Inc. – Increased ownership by 2% in Q3 2023.
- The Vanguard Group, Inc. – Increased ownership by 1.5% in Q3 2023.
- Renaissance Technologies LLC - Acquired 300,000 shares in Q3 2023.
Future Ownership Projections
Analysts predict that the ownership stakes of institutional investors may grow given the increasing interest in biopharmaceutical companies focusing on immunotherapy. Current forecasts suggest that by 2025, institutional ownership could reach upwards of 35%.
OncoSec Medical Incorporated (ONCS) Mission Statement
Company Overview
OncoSec Medical Incorporated focuses on the development of innovative therapies to treat cancer. The company's mission is to harness the power of the immune system to fight cancer through its proprietary technologies.
Mission Statement
The mission of OncoSec Medical Incorporated is to improve patient outcomes by developing breakthrough therapies that activate the immune system to recognize and destroy cancer cells. Their goal is to deliver these cutting-edge immunotherapies to patients suffering from various types of cancers.
Core Values
- Innovation: Commitment to pioneering new technologies and treatment methodologies.
- Integrity: Adherence to the highest ethical standards in clinical research and business practices.
- Collaboration: Engaging with healthcare professionals, researchers, and patients to advance cancer treatment.
- Compassion: Providing support to patients and families affected by cancer.
Recent Financial Performance
As of the fiscal year ending July 31, 2023, OncoSec reported the following financial metrics:
| Metric | Value |
|---|---|
| Total Revenue | $1.2 million |
| Net Loss | $(10.5) million |
| Cash and Cash Equivalents | $17 million |
| Research and Development Expenses | $(6.8) million |
| General and Administrative Expenses | $(3.5) million |
Product Pipeline
OncoSec’s lead product candidate, ONCOS-102, is in clinical development. The clinical trials are focused on melanoma and other solid tumors:
| Product Candidate | Indication | Phase |
|---|---|---|
| ONCOS-102 | Melanoma | Phase 2 |
| ONCOS-102 | Head and Neck Cancer | Phase 2 |
| ONCOS-100 | Breast Cancer | Phase 1 |
Recent Developments
- In October 2023, OncoSec announced positive interim results from its Phase 2 clinical trial.
- The company secured a partnership with a leading cancer research center to enhance its clinical capabilities.
- OncoSec received FDA Fast Track Designation for ONCOS-102 in melanoma treatment.
Market Potential
The global immunotherapy market is projected to reach approximately $168 billion by 2026, with a CAGR of 12.1% from 2021. OncoSec aims to establish itself as a key player in this growing sector.
Future Outlook
OncoSec Medical is dedicated to expanding its clinical trials and accelerating the development of its immunotherapies. The company is focused on addressing the unmet medical needs in oncology through its promising research programs.
How OncoSec Medical Incorporated (ONCS) Works
Overview of OncoSec Medical Incorporated
Overview of OncoSec Medical Incorporated
OncoSec Medical Incorporated, traded on NASDAQ under the ticker ONCS, is a biotechnology company focused on developing and commercializing innovative therapeutics for the treatment of cancer. Their pipeline includes the use of electroporation technology to enhance the delivery of therapeutic agents into cancer cells.
Technology and Product Portfolio
The company's core technology, known as Illumination, employs electroporation to facilitate the uptake of antigen-encoding plasmid DNA into cells. This technology is primarily aimed at treating solid tumors. Their main product candidates include:
- OMS-102: A therapeutic candidate for melanoma.
- OMS-201: Targeting triple-negative breast cancer.
- PENTAGLO™: A combination of benzonase and electroporation for squamous cell carcinoma.
Recent Financial Performance
As of the end of Q3 2023, OncoSec reported:
- Total Revenue: $0.5 million
- Net Loss: $3.4 million
- Cash and Cash Equivalents: $15.2 million
Clinical Trials and Progress
OncoSec is involved in several clinical trials across various stages. As of October 2023, the status of their main programs is as follows:
| Product Candidate | Trial Phase | Indication | Completion Date |
|---|---|---|---|
| OMS-102 | Phase 2 | Melanoma | Q2 2024 |
| OMS-201 | Phase 1 | Triple-negative breast cancer | Q4 2023 |
| PENTAGLO™ | Preclinical | Squamous cell carcinoma | Not disclosed |
Market Potential and Strategy
The global market for cancer therapeutics is valued at an estimated $150 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.5% by 2030. OncoSec's strategic focus includes:
- Partnerships: Collaborating with larger pharmaceutical companies for development and marketing.
- Geographical Expansion: Targeting emerging markets that show high growth potential.
- Innovation: Continuously advancing their technology to improve treatment efficacy and safety.
Stock Performance and Market Capitalization
As of October 2023, ONCS has a market capitalization of approximately $50 million. The stock has demonstrated volatility, trading between $0.30 and $1.20 per share over the last 12 months.
Challenges and Risks
OncoSec faces various challenges and risks, including:
- Regulatory Approval: Uncertainty in obtaining FDA approvals for their products.
- Funding: Continued need for capital to support ongoing trials and operations.
- Market Competition: Intense competition from other oncology-focused biotech firms.
Conclusion
N/A
How OncoSec Medical Incorporated (ONCS) Makes Money
Revenue Generation through Clinical Trials
OncoSec Medical Incorporated primarily generates revenue by conducting clinical trials for its product candidates aimed at cancer treatment. The company is engaged in developing its proprietary immunotherapy technology, called OMS-I100, for treating various forms of cancer, including melanoma and other solid tumors.
Partnerships and Collaborations
OncoSec also seeks financial support and expertise through strategic partnerships. For instance, in recent years, the company has collaborated with major pharmaceutical companies and research institutions to enhance its clinical development efforts. As of 2023, OncoSec reported having entered into collaborations that could generate substantial future revenues based on milestone achievements and product sales.
Equity Financing
In addition to operational revenue, OncoSec has utilized equity financing as a method of raising capital. For example, in 2021, OncoSec conducted a registered direct offering of approximately $13.7 million with leading institutional investors, which was used to fund its clinical trials and R&D.
Government Grants and Funding
OncoSec has pursued government grants to support its research initiatives. The company has received funding from the National Institutes of Health (NIH) totaling approximately $2.5 million over various fiscal years to support its immunotherapy projects.
Table of Recent Financial Performance
| Year | Revenue | Net Loss | Total Assets | Total Liabilities |
|---|---|---|---|---|
| 2021 | $0 | $(10.2 million) | $34.1 million | $14.6 million |
| 2022 | $0 | $(12.4 million) | $22.5 million | $8.9 million |
| 2023 (Q2) | $0 | $(8.0 million) | $15.0 million | $6.5 million |
Investment in Research and Development
OncoSec invests heavily in its R&D efforts, which is a core component of its strategy. In recent reviews, the company allocated approximately 80% of its budget towards R&D expenses, which totaled around $9 million in 2022.
Market Potential and Future Revenue Streams
The potential market for OncoSec’s therapies is significant. With the global immunotherapy market projected to reach $131 billion by 2026, OncoSec aims to capture a percentage of this growth through successful clinical trials and subsequent product approvals.
Licensing Revenue
Should OncoSec secure approvals for its therapies, licensing agreements can become a critical revenue source. The company aims to license its technologies to larger pharmaceutical firms, which forms part of its long-term financial strategy.
Table of Key Collaborations and Financial Implications
| Partner | Type of Collaboration | Potential Milestone Payments | Product Focus |
|---|---|---|---|
| Merck | Clinical trial collaboration | $5 million | Combination therapies |
| Bristol-Myers Squibb | Research partnership | $3 million | Immuno-oncology |
| Academic Institutions | Research grants | N/A | Novel therapies |
OncoSec Medical Incorporated (ONCS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support